Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (33358)	1/13/2010 12:44:48 PM
From: A.J. Mullen	Respond to of 52153

Elan Neurology neurodegenerative (adpd and ms), and pharmacology 20 % revenue growth flat to down costs Headcount down 70%, 65% reduction in debt AIP (Alzheimers) next $1billion cost cover by J&J and Pfizer, the following $1B will cost Elan 250 million. Get 50% of profits. J&J have 18(?)% stake in company. Tysabri Patients and revenue up by 30%. PML is the one downside. IF JVC (50-60% population) infection then some chance of PML. Working on antibody test. Tysabri fundamental to company. Expand indications and geography (Mexico, Brazil, Turkey..) I don't hold this stock - Ashley